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Introduction {#sec001}
============

RNA has over 100 different post-transcriptional modifications that have been identified in organisms across all three domains of life \[[@pone.0225064.ref001]--[@pone.0225064.ref005]\]. While several RNA modifications have been recently identified on mRNAs in yeast, plants, and animals, tRNAs are still thought to be the most extensively modified cellular RNAs \[[@pone.0225064.ref006]--[@pone.0225064.ref009]\]. These tRNA modifications are introduced at the post-transcriptional level by specific enzymes. These enzymes recognize polynucleotide substrates and modify individual nucleotide residues at highly specific sites. Some tRNA modifications have been shown to have a clear biological and molecular function \[[@pone.0225064.ref010], [@pone.0225064.ref011]\]. Several tRNA modifications around the anticodon have been demonstrated to have crucial functions in translation, for example, by enhancing decoding \[[@pone.0225064.ref012]\], influencing the propensity to ribosomal frameshifting or facilitating wobbling \[[@pone.0225064.ref013]--[@pone.0225064.ref015]\]. Modifications distal to the tRNA anticodon loop can also directly influence the tRNA recognition and/or translation process \[[@pone.0225064.ref016]\] or can have roles in tRNA folding and stability \[[@pone.0225064.ref001], [@pone.0225064.ref017]\]. However, the precise functions of many tRNA modifications still remain unknown despite often being conserved across species. Often, loss of a tRNA modification does not negatively impair cell growth or cell viability under standard laboratory growth conditions \[[@pone.0225064.ref018]\]. However, under environmental stress, such mutants display a discernible phenotype \[[@pone.0225064.ref011]\].

The tRNA anticodon loop position 37 is important to maintain translational fidelity, prevent frameshift errors and translational efficiency \[[@pone.0225064.ref010], [@pone.0225064.ref019]--[@pone.0225064.ref021]\], and almost all tRNAs are modified at this site. There are two prominent modifications at tRNA position 37: N^1^-methylguanosine (m^1^G37) and 1-methylinosine (m^1^I). Trm5 in humans, yeast, and *Pyrococcus abyssi* has been described as having multifunctionality \[[@pone.0225064.ref022]--[@pone.0225064.ref024]\]. N^1^-methylation of guanosine at position 37, m^1^G37, is performed by TrmD-type enzymes in bacteria, functionally and evolutionarily unrelated Trm5-type proteins in Archaea and Eukaryote, Trm5p in yeast *Saccharomyces cerevisiae*, and TRMT5 *in vivo* in humans \[[@pone.0225064.ref021]--[@pone.0225064.ref023], [@pone.0225064.ref025]--[@pone.0225064.ref027]\]. Trm5p complete loss of function mutants in yeast *Saccharomyces cerevisiae* are lethal whereas mutations in TRMT5 lead to multiple respiratory-chain deficiencies and a reduction in mitochondrial tRNA m^1^G37 \[[@pone.0225064.ref010], [@pone.0225064.ref023], [@pone.0225064.ref026]\]. In humans, TRMT5 (tRNA methyltransferase 5) catalyses the formation of m^1^G37 *in vivo* on mitochondrial tRNA^Pro^ and tRNA^Leu^ \[[@pone.0225064.ref022], [@pone.0225064.ref028]\]. N^1^-methylguanosine has been described in eukaryotic tRNAs at two positions; at position 37 catalysed by Trm5, and the other at position 9 catalysed by Trm10 \[[@pone.0225064.ref029]\]. In contrast to bacteria TrmD, which requires a guanosine at position 37, human TRMT5 can also recognise and methylate inosine at position 37 with some limited activity \[[@pone.0225064.ref022]\]. Similarly,Trm5p has also been shown to catalyse inosine to m^1^I modification in yeast in a two-step reaction, where the first adenosine-to-inosine modification was mediated by Tad1p \[[@pone.0225064.ref011], [@pone.0225064.ref018], [@pone.0225064.ref026], [@pone.0225064.ref030]\]. As m^1^G is an intermediate during the modification of guanosine to wybotusine (yW), tRNAs from *trm5* mutants were also devoid of yW \[[@pone.0225064.ref028]\]. The yeast Trm5p protein has been shown to be localised to the cytoplasm and mitochondria and it is thought that Trm5p protein present in the mitochondria is required to prevent unmodified tRNA affecting translational frameshifting \[[@pone.0225064.ref023], [@pone.0225064.ref026]\]. In the unicellular parasite *Trypanosome brucei*, Trm5 was located in both the nucleus and mitochondria and reducing Trm5 expression led to reduced mitochondria biogenesis and impaired growth \[[@pone.0225064.ref031]\]. Interestingly, Trm5 and m^1^G37 were shown to be essential for mitochondrial protein synthesis but not cytosolic translation \[[@pone.0225064.ref031]\].

Little is known about tRNA modifying enzymes in plants, especially the plant homolog of this bifunctional methyltransferase. Here, we report the identification and functional analysis of *AtTRM5* (At3g56120) from the model plant *Arabidopsis thaliana*. We demonstrate that *Attrm5* mutant plants are slower growing, have reduced shoot and root biomass and display late flowering. Furthermore, we demonstrate that *in vitro TRM5* is required for m^1^G37 and m^1^I37 methylation at the position 3' to the anticodon and *in vivo* tRNAs enriched from *Attrm5* plants have reduced m^1^G and m^1^I.

Results {#sec002}
=======

Identification of At3g56120 as a TRM5 homolog {#sec003}
---------------------------------------------

In yeast (*Saccharomyces cerevisiae*), m^1^G37 nucleoside modification is catalysed by Trm5p/ScTrm5 \[[@pone.0225064.ref026]\]. We searched for *Arabidopsis thaliana* homologs by using blastp and HMMER and identified a high confidence candidate, At3g56120, with 49% similarity to ScTrm5 ([S2 Fig](#pone.0225064.s002){ref-type="supplementary-material"}). Alignment of At3g56120 with yeast, human, *Drosophilia*, *Pyrocococcus*, and *Methanococcus* Trm5 homologs identified three conserved motifs and catalytically required amino acids (R166, D192, E206) present in At3g56120 ([S2 Fig](#pone.0225064.s002){ref-type="supplementary-material"}). We subsequently will refer to At3g56120 as AtTRM5. In the *Arabidopsis* genome, AtTrm5 has homology to At4g27340 and At4g04670 and both genes were recently named as TRM5B and TRM5C, respectively ([S2 Fig](#pone.0225064.s002){ref-type="supplementary-material"} and \[[@pone.0225064.ref032]\]). We have also identified TRM5 homologs in algae, bryophytes and vascular plants ([Fig 1A](#pone.0225064.g001){ref-type="fig"} and [S1 Fig](#pone.0225064.s001){ref-type="supplementary-material"}). We focussed our experiments on *Arabidopsis* At3g56120/AtTRM5 as the protein had the highest amino acid similarity to yeast ScTrm5.

![TRM5 is conserved in plants and has dual-functionality in modifying RNA bases.\
(**A**) Unrooted phylogenetic tree and sequence conservation Circos plot of putative TRM5 proteins from yeast (Sc), tomato (Sl), grape (Vv), *Arabidopsis* (At), maize (Zm), rice (Os), *Marchantia* (Mp), *Physcomitrella* (Pp), *Chlamydomonas* (Cr), and *Ostreococcus* (Ot). The ribbons were coloured based on sequence identity, with blue \< = 25%, green 25--50%, orange 51--75% and red for 76--99%. (**B**) Exon-intron structure of the putative TRM5 locus (At3g56120) showing the T-DNA insertion sites of the *trm5-1* and *trm5-2* alleles (as indicated by the open triangles). Black boxes and grey boxes represent coding regions and untranslated regions, respectively. (**C**) Relative transcript level detected by qPCR in wild type, *trm5-1* or *trm5-2* seedlings. (**D**) Relative nucleoside level of modification m^1^G and m^1^I detected by HPLC/MS in wild type, *trm5-1* or *trm5-2* seedlings.](pone.0225064.g001){#pone.0225064.g001}

To functionally characterize AtTRM5 we isolated two T-DNA insertions, SALK_022617 and SALK_032376, and identified homozygous mutant plants for each insertion ([Fig 1B](#pone.0225064.g001){ref-type="fig"}). SALK_022617 and SALK_032376 were named *trm5-1* and *trm5-2*, respectively. Next, we measured AtTRM5 mRNA abundance in both mutants and detected almost no transcripts in both mutants ([Fig 1C](#pone.0225064.g001){ref-type="fig"}). We generated a genomic construct of AtTRM5 that contained the endogenous promoter, coding region, and UTRs, transformed the construct into *trm5-2* and demonstrated that the AtTRM5 mRNA levels were similar in two complemented lines when compared to wild type plants. Subsequently, the extracted tRNAs from wild type and the *trm5* mutants were purified, digested and modified nucleosides measured by mass spectrometry ([Fig 1D](#pone.0225064.g001){ref-type="fig"}). In both *trm5* mutant alleles, nucleoside m^1^G levels were reduced to about 30% of the wild type and m^1^G levels were restored to wild type levels in both complemented lines ([Fig 1D](#pone.0225064.g001){ref-type="fig"}). Nucleoside m^1^G is present at tRNA positions 9 and 37 \[[@pone.0225064.ref026]\], therefore the residual m^1^G levels in *trm5* mutants may be the result of tRNA m^1^G at position 9. In saying this, we cannot exclude an alternative explanation that the residual m^1^G levels in *trm5* plants are the result of activity of either TRM5B or TRM5C.

In yeast, Trm5 has also been reported to also catalyse m^1^I on tRNAs \[[@pone.0225064.ref011], [@pone.0225064.ref026]\]. We therefore measured m^1^I levels in purified tRNAs from both *Arabidopsis trm5* mutants and wild type control plants. In both *trm5-1* and *trm5-2* mutant alleles, nucleoside m^1^I levels were reduced to about 10% of wild type levels and were restored to wild type levels in plants of both complemented lines ([Fig 1D](#pone.0225064.g001){ref-type="fig"}). It is possible that the residual m^1^I in *trm5* plants may be m^1^I at position 57 \[[@pone.0225064.ref004], [@pone.0225064.ref033], [@pone.0225064.ref034]\]. In summary, we identified At3g56120 as a TRM5 homolog in *Arabidopsis thaliana*, identified two AtTRM5 mutant alleles, *trm5-1* and *trm5-2*, and both mutants showed a significant reduction in m^1^G and m^1^I.

AtTRM5 is involved in leaf and root development and flowering time regulation {#sec004}
-----------------------------------------------------------------------------

Before undertaking growth measurements, we grew wild-type Columbia, *trm5-1*, two complemented lines, and two overexpression lines together under long-day conditions, harvested and dried the seeds to minimise any maternal or environmental effects. To observe the early growth stages of seedlings, we grew the six lines (wild type, *trm5-1*, two complemented lines and two overexpression lines) on plates for 10 days ([Fig 2A](#pone.0225064.g002){ref-type="fig"}). The *trm5-1* seedlings were noticeably smaller than the wild type. In contrast, no clear differences were evident between wild type, the complemented and overexpression lines. To rule out the possibility that the reduced growth in *trm5-1* seedlings was due to slower germination, we measured the germination of *trm5-1* and wild type and no difference was observed ([S3 Fig](#pone.0225064.s003){ref-type="supplementary-material"}). Reduced growth of *trm5-1* roots was also evident on plate-grown plants ([Fig 2B](#pone.0225064.g002){ref-type="fig"}). Interestingly, *trm5-1* primary, lateral and total (primary + lateral) root lengths were reduced in *trm5-1* when compared to wild-type plants ([S4 Fig](#pone.0225064.s004){ref-type="supplementary-material"}). We also measured the lateral root number and found that *trm5-1* plants had reduced numbers when compared to the wild type ([S4 Fig](#pone.0225064.s004){ref-type="supplementary-material"}). In contrast, no differences in the root growth were evident upon comparison of the wild type and the complemented lines. In *TRM5* overexpression lines, primary and lateral root lengths were slightly longer than in the wild type ([Fig 2B](#pone.0225064.g002){ref-type="fig"} and [S4 Fig](#pone.0225064.s004){ref-type="supplementary-material"}).

![Phenotype analysis of *trm5*, complemented lines (35S:TRM5 *trm5-1*) and TRM5 overexpression lines (35S:TRM5).\
(**A**) Seedlings were sown on ½ MS media plates and grown for 7 days and photographed. (**B**) Seedlings of wild type, *trm5*, complemented lines (35S:TRM5 *trm5-1*), TRM5 overexpression lines (35S:TRM5) were vertically grown on ½ MS medium for 10 days and then photographed. (**C**) Plants were grown on soil under long day photoperiods and photographed 15 days after germination. (**D**) Wild type, *trm5-1*, two complementing (35S:TRM5 *trm5-1*) and two overexpressing lines (35S:TRM5) were grown under long days and representative plants photographed at flowering.](pone.0225064.g002){#pone.0225064.g002}

At inflorescence emergence in wild-type plants grown under long days, we observed reduced rosette leaf numbers, smaller leaves and reduced fresh weight in *trm5-1* plants ([Fig 2C and 2D](#pone.0225064.g002){ref-type="fig"}; [S3 Fig](#pone.0225064.s003){ref-type="supplementary-material"}). Sectioning of the shoot apical meristems of wild type and *trm5-1* plants at wild-type floral transition, confirmed that *trm5* plants were later flowering ([S3 Fig](#pone.0225064.s003){ref-type="supplementary-material"}). We measured the flowering time of wild type, *trm5-1*, complemented, and overexpression lines under both short and long days and observed that mutants produced more rosette leaves and flowered later than the wild type ([Fig 3A](#pone.0225064.g003){ref-type="fig"}; [S3 Fig](#pone.0225064.s003){ref-type="supplementary-material"}). Plants overexpressing TRM5 flowered slightly earlier than wild type under both long and short-day conditions ([Fig 2D](#pone.0225064.g002){ref-type="fig"}; [S3 Fig](#pone.0225064.s003){ref-type="supplementary-material"}).

![More leaves, slower flowering and impacted photosynthetic genes in trm5 mutant of *Arabidopsis thaliana*.\
(**A**) Rosette leaf number (long-day conditions), cauline leaf number and days to flower (short day conditions) of wild type and *trm5* mutant. (**B**) The mRNA abundance of circadian clock-related genes over a 24-hour period. 17-day-old seedlings of wild type, *trm5-1*, complemented lines (35S:TRM5 *trm5-1*), TRM5 overexpression lines (35S:TRM5) were grown on ½ MS medium for 10 days and then harvested every 3 hours. The expression levels of *TOC1*, *PRR7*, GI, CO, *FT*, and LFY were measured and normalized relative to *EF-1-α*. Data presented are means. Error bars are ± SE, n = 3 biological replicates. An asterisk indicates a statistical difference (*P*\<0.05) as determined by Student's t-test. 0 hours is lights on and 16 hours is light off. Shaded area indicates night, whereas Zeitgeber time is abbreviated as ZT.](pone.0225064.g003){#pone.0225064.g003}

AtTRM5 is involved in circadian clock and flowering time gene expression {#sec005}
------------------------------------------------------------------------

To explore the molecular basis of delayed flowering in *trm5-1*, we measured the mRNA abundance of circadian clock and flowering time related genes by quantitative RT-PCR over a 24-hour period ([Fig 3](#pone.0225064.g003){ref-type="fig"}). In *trm5-1* plants, lower abundance of the clock genes *TIMING OF CAB EXPRESSION 1* (*TOC1*), and *PSEUDO RESPONSE REGULATOR 7* (*PPR7*), and the flowering time regulator genes *GIGANTEA (GI)*, *CONSTANS (CO)* and *FLOWERING LOCUS T (FT)* were observed at ZT10 to ZT22. The reduced abundance of the flowering time regulators *GI*, *CO*, and *FT* in *trm5-1* mutants correlates with delayed flowering. As expected, the downstream floral meristem identity gene *LEAFY (LFY)* had lower abundance at almost all tested time points in the *trm5* mutant when compared to wild type ([Fig 3B](#pone.0225064.g003){ref-type="fig"}). The downregulation of circadian-clock related genes were also detected in the RNA-seq data ([S2 Table](#pone.0225064.s007){ref-type="supplementary-material"}). Together these results support a role for AtTRM5 in plant growth, development, and flowering time regulation.

AtTRM5 m^1^G methyltransferase activity {#sec006}
---------------------------------------

To test AtTRM5 m^1^G methyltransferase activity *in vivo*, a *Δtrm5* mutant strain in yeast *(Saccharomyces cerevisiae*, Sc) that is defective for the tRNA m^1^G37 modification was used for genetic complementation. The mutant not only has defective tRNA m^1^G37 but also a slow growth phenotype when compared to wild type or a congenic strain ([Fig 4A](#pone.0225064.g004){ref-type="fig"}). Full-length *ScTrm5* and *AtTRM5* were cloned into yeast expression vectors. From the *AtTRM5* expression vector, a catalytically inactive mutant *Attrm5* R166D was generated by site-directed mutagenesis. After the three vectors had been transformed into the yeast *Δtrm5* mutant, cell growth and m^1^G nucleoside levels were observed ([Fig 4](#pone.0225064.g004){ref-type="fig"}). Not only were the slow growth and nucleoside levels rescued when expressing *ScTrm5* but they were also rescued when expressing *AtTRM5* ([Fig 4A and 4B](#pone.0225064.g004){ref-type="fig"}). However, the catalytically inactive Attrm5 R166D did not rescue either the slow growth or m^1^G nucleoside levels ([Fig 4A and 4B](#pone.0225064.g004){ref-type="fig"}).

![TRM5 modifies tRNA~37~ guanosine (G) to m^1^G in yeast.\
(**A**) Serial-dilution growth assay. Complementation experiment of TRM5 from yeast (Sc), *Arabidopsis thaliana* (At) or a catalytically inactive mutant AtTrm5 R166D in the yeast *trm5* mutant. (**B**) Relative nucleoside level of modification m^1^G quantified by HPLC/MS of each complemented yeast strains with either ScTRM5 or AtTRM5. (**C**) Proposed model of TRM5-mediated m^1^G modification of yeast tRNA-Asp. (**D**) Relative nucleoside level of modification m^1^G with varying conditions of tRNA-Asp-G37, AtTRM5, AtTRM5 catalytic mutant, and tRNA-Asp-A37. + indicates presence, ++ indicates two-fold increase,---indicates absence.](pone.0225064.g004){#pone.0225064.g004}

To test the m^1^G methyltransferase activity of AtTRM5 *in vitro*, we incubated purified recombinant proteins with tRNA substrates and measured the m^1^G levels. We expressed *AtTRM5* as a GST fusion protein and purified the recombinant GST-AtTRM5 protein. We also generated a catalytically inactive GST-AtTRM5 recombinant protein by using site directed mutagenesis, expressed and purified the GST-AtTRM5 recombinant fusion protein. In yeast, ScTrm5 methylates tRNA-His-GUG, tRNA-Leu-UAA, tRNA-Asp-GUC and other tRNA isoacceptors \[[@pone.0225064.ref011], [@pone.0225064.ref026], [@pone.0225064.ref032]\]. Yeast tRNA-Asp-GUC RNA transcripts were generated *in vitro* by using T7 RNA polymerase, the tRNA transcripts incubated with the recombinant fusion proteins in the presence of AdoMet and m^1^G nucleoside levels were measured ([Fig 4D](#pone.0225064.g004){ref-type="fig"}). m^1^G was detected only when AtTRM5 was provided ([Fig 4D](#pone.0225064.g004){ref-type="fig"}) and in a dosage dependent manner. No m^1^G was detected when the catalytically inactive mutant AtTRM5 was provided ([Fig 4D](#pone.0225064.g004){ref-type="fig"}). To test the specificity of the methyltransferase activity on tRNA-Asp guanine at position 37, the guanine nucleotide was mutated to an adenine nucleotide (tRNA-Asp-A37) and the m^1^G methyltransferase activity was measured. No m^1^G was detected after incubation with the fusion proteins ([Fig 4D](#pone.0225064.g004){ref-type="fig"}). The overall results of the yeast complementation experiments suggest that guanosine methylation occurred at position 37 of tRNA.

AtTRM5 tRNA m^1^I methyltransferase activity {#sec007}
--------------------------------------------

Previously in plants, TAD1 was demonstrated to oxidatively deaminate adenosine at position 37 of tRNA-Ala-(UGC) to inosine, and subsequently methylated by an unknown enzyme to N1-methylinosine (m^1^I; [Fig 5A](#pone.0225064.g005){ref-type="fig"}). Human TRM5 has been reported to methylate tRNA I37 but with limited activity \[[@pone.0225064.ref022]\]. Given our observation that *Attrm5* mutant plants had reduced m^1^I ([Fig 1D](#pone.0225064.g001){ref-type="fig"}), we asked the question whether AtTRM5 has methyltransferase activity on tRNA I37. We developed a two-step approach, whereby purified AtTAD1 was first incubated with the substrate tRNA-Ala-A37 to produce tRNA-Ala-I37 and then the inosine methyltransferase activity of AtTRM5 was measured by incubating AtTRM5 with the tRNA-Ala-I37 substrate. Previously, in yeast ScTAD1 was demonstrated to deaminate tRNA-Ala-A37 to tRNA-Ala-I37 *in vitro* \[[@pone.0225064.ref026]\] and *Arabidopsis thaliana tad1* mutants were reported to have reduced tRNA-Ala-I37 \[[@pone.0225064.ref011]\]. We expressed *AtTAD1* as a GST fusion protein and purified the recombinant GST-AtTAD1 protein. We also generated a catalytically inactive GST-AtTAD1 mutant recombinant protein by using site-directed mutagenesis and expressed and purified the GST-AtTAD1 mutant fusion protein. In a two-step assay, yeast tRNA-Ala-UGC RNA transcripts were generated by *in vitro* transcription using T7 RNA polymerase, the tRNA transcripts were then incubated with the recombinant fusion proteins in the presence of Mg^2+^ and methyl donor S-adenosyl-methionine (AdoMet), and the m^1^I nucleoside levels measured ([Fig 5B](#pone.0225064.g005){ref-type="fig"}). m^1^I was detected only when GST-AtTAD1 and GST-AtTRM5 were provided, and its production occurred in a dosage-dependent manner ([Fig 5B](#pone.0225064.g005){ref-type="fig"}). No m^1^I was detected when the catalytically inactive mutants AtTAD1 E76S or AtTRM5 R166D were provided ([Fig 5B](#pone.0225064.g005){ref-type="fig"}). To test the specificity of the methyltransferase activity on tRNA-Ala alanine at position 37, the alanine nucleotide was mutated to a cytosine nucleotide (tRNA-Ala-C37) and the m^1^I methyltransferase activity was measured. No m^1^I was detected after incubation with the fusion proteins ([Fig 5B](#pone.0225064.g005){ref-type="fig"}). Collectively, these findings interestingly suggest that inosine methylation also occurs at position 37, in addition to guanosine methylation.

![TRM5-mediated m^1^I modifications in two-step reaction.\
(**A**) Proposed two-step modification model of TRM5-mediated m^1^G modification of tRNA-Ala. (**B**) Relative nucleoside level of modification m^1^I with varying conditions of tRNA-Asp-A37, AtTAD1, AtTRM5 mutant, AtTAD1 mutant, and tRNA-Ala-C37. + indicates presence, ++ indicates two-fold increase,---indicates absence. (**C**) Qualitative analysis of tRNA-Ala^(TGC)^ and tRNA-Ala^(CGC)^ modifications. tRNAs were enriched, deep sequenced, aligned using segemehl to tRNA references and the modifications present were inferred from observed base substitutions between wild type and *trm5-1*. Position 37 in the gDNA, labelled as consensus, is an adenine. Sequence logo shows the proportion of nucleotides and hence inferred modifications at positon 37. Anticodons TGC and CGC are shown in the sequence logos for Ala^(TGC)^ and tRNA-Ala^(CGC)^, respectively. Base substitutions observed from 3 biological replicates are shown. (**D**) Qualitative analysis of tRNA-Ala^(AGC)^ modifications by Sanger sequencing. tRNA-Ala^(AGC)^ was PCR amplified from wild type, *tad1-2* and *trm5-1* and Sanger sequenced. Position 37 in the gDNA is an adenine. In wild-type cDNA, a thymine was detected, in *tad1-2* cDNA an adenine was observed and in *trm5-1* a guanine was detected.](pone.0225064.g005){#pone.0225064.g005}

To test the AtTRM5 inosine methyltransferase activity *in vivo*, we measured tRNA position modifications by cDNA sequencing from either mutant or wild type plants ([Fig 5C and 5D](#pone.0225064.g005){ref-type="fig"}). In the sequencing assay, modification events at position 37 of tRNAs can be directly detected by sequencing of amplified cDNA obtained by reverse transcription and comparison to the DNA reference sequence as inosine is read as guanine (G) and m^1^I is read as thymine (T) by the reverse transcriptase \[[@pone.0225064.ref010], [@pone.0225064.ref035]\]. As expected, we detected substitutions of A in the reference to T at position 37 for tRNA-Ala-(TGC) and tRNA-Ala-(CGC) by using Illumina sequencing in wild-type plants which is consistent with the presence of m^1^I ([Fig 5C](#pone.0225064.g005){ref-type="fig"}). m^1^I modifications have previously been described in tRNA-Ala at position 37 in eukaryotes \[[@pone.0225064.ref011], [@pone.0225064.ref030], [@pone.0225064.ref033]\]. In the *trm5-1* mutant, no T's were detected at position 37 ([Fig 5C](#pone.0225064.g005){ref-type="fig"}) which is consistent with AtTRM5 acting as a tRNA m^1^I methyltransferase at position 37. Based on our *in vitro* assay results, AtTAD1 first deaminates tRNA-Ala-A37 to tRNA-Ala-I37, and then AtTRM5 methylates tRNA-Ala-I37 to tRNA-Ala-m^1^I37. We confirmed this pathway in *tad1* and *trm5* mutant plants by Sanger sequencing of tRNA-Ala-(AGC) ([Fig 5D](#pone.0225064.g005){ref-type="fig"}). As expected, at position 37, A was substituted to T in the wild type, whereas in *trm5* mutants a G and in *tad1* mutants an A were observed ([Fig 5D](#pone.0225064.g005){ref-type="fig"}). These sequencing results are consistent with AtTAD1 first deaminating A37 to I37 as previously reported by Zhou, Karcher (11), and AtTRM5 then methylating I37 to m^1^I. We also attempted to detect the putative loss of m^1^G in the tRNA-sequencing data, as it has been reported that m^1^G is prone to be called as a T in sequencing \[[@pone.0225064.ref035]\]. However, this was not observed in our datasets. Together, our *in vitro* and *in vivo* data provide support for AtTRM5 possessing tRNA m^1^I methyltransferase activity.

AtTRM5 is localized to the nucleus {#sec008}
----------------------------------

In yeast, ScTRM5 is localized to both the nucleus and mitochondria \[[@pone.0225064.ref023], [@pone.0225064.ref036]\]. Localisation to mitochondria is thought to be important as yeast strains with only nuclear-localized ScTRM5 exhibited a significantly lower rate of oxygen consumption \[[@pone.0225064.ref023]\]. In order to determine to which subcellular compartment(s) AtTRM5 is localized in *Nicotiana benthamiana*, we fused TRM5 to the Green Fluorescent Protein (GFP) reporter, transiently infiltrated the construct into leaves and performed laser-scanning confocal microscopy to detect GFP fluorescence. To unambiguously identify the nucleus, we stained the cells with DAPI. When we imaged the cells (n = 100), we observed distinct DAPI fluorescence in a single large circular structure per cell, as expected for the nucleus ([Fig 6](#pone.0225064.g006){ref-type="fig"}). Next, we imaged the same cells for GFP fluorescence ([Fig 6C](#pone.0225064.g006){ref-type="fig"}) and overlayed the DAPI and GFP fluorescence. The two fluorescence signals showed perfect overlap ([Fig 6D](#pone.0225064.g006){ref-type="fig"}). We then searched for nuclear localisation signals (NLS) using the LOCALIZER (<http://localizer.csiro.au/>), LocSigDB (<http://genome.unmc.edu/LocSigDB/>), and cNLS mapper (<http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi>) programs \[[@pone.0225064.ref037]--[@pone.0225064.ref039]\]. While LOCALIZER and LocSigDB did not predict any canonical or bipartite NLS, cNLS mapper predicted with high confidence a 29 amino acid importin α-dependent NLS, QKGCFVYANDLNPDSVRYLKINAKFNKVD, that starts at amino acid 236. Previous finding in yeast suggested that no common canonical or bipartite NLS was detected in ScTrm5 \[[@pone.0225064.ref026]\], which explains the outcome from LOCALIZER and LocSigDB. Multiple sequence alignment of ScTrm5 and AtTRM5 showed that only a few amino acids were conserved at the region which the importin α-dependent NLS is detected for AtTRM5 ([S2 Fig](#pone.0225064.s002){ref-type="supplementary-material"}). In summary, we conclude that, unlike in yeast, AtTRM5 in *Arabidopsis* is only localized to the nucleus and may be imported from the cytoplasm into the nucleus by the importin α-dependent pathway.

![Subcellular localisation of TRM5 translational reporter protein in *Nicotiana benthamiana* leaves.\
TRM5 was fused to Green Fluorescent Protein (GFP) to yield a TRM5-GFP translational fusion recombinant protein. The construct was transiently expressed in *N*. *benthamiana* leaves and subcellular localisation was determined by confocal laser-scanning microscopy. (**A**) Bright field, (**B**) DAPI stained, (**C**) GFP fluorescence, (**D**) overlay of DAPI and GFP imagines. Scale bars = 20 μm.](pone.0225064.g006){#pone.0225064.g006}

Proteins involved in photosynthesis are affected in *trm5* mutant plants {#sec009}
------------------------------------------------------------------------

Next, we performed a proteomic analysis to identify proteins that differentially accumulate in *trm5-1* plants when compared to the wild type by using the Tandem Mass Tag (TMT) method ([Fig 7](#pone.0225064.g007){ref-type="fig"}). A total of 61571 peptide-spectrum match (PSM) were recorded, corresponding to 29011 peptides and 23055 unique peptides, respectively. 5242 protein groups were identified by blastp searches against the TAIR_pep database. Proteins with fold changes ≥1.20 or ≤0.83 and a significance level of *P* ≤0.05 were considered to be differentially expressed. In this way, a total of 263 proteins were identified ([S3 Table](#pone.0225064.s008){ref-type="supplementary-material"}). 102 proteins were upregulated, and 151 proteins were downregulated in *trm5* ([Fig 7A](#pone.0225064.g007){ref-type="fig"}). GO annotation of these differentially accumulating proteins revealed enrichment of the GO terms thylakoid, chloroplast, and photosystem I ([Fig 7B](#pone.0225064.g007){ref-type="fig"}). KEGG annotation revealed enrichment of proteins involved in photosynthesis, and photosynthetic proteins, with most of these proteins encoded by genes found in the nuclear and chloroplast genome. ([Fig 7C](#pone.0225064.g007){ref-type="fig"}). A further inspection on these GO terms with our proteomics data showed that the photosynthesis-related proteins were downregulated in *trm5* mutant. In the future, the abundance of these photosynthesis-related proteins could be validation by quantitative western blotting analysis. It is worthwhile to state that the abundance of these photosynthesis-related proteins may be directly or indirectly affected by the loss of TRM5 in our experiment. Taken together, the GO and KEGG analysis demonstrated that most differentially accumulating proteins are involved in processes related to photosynthesis.

![Proteomic analysis of wild type and *trm5-1*.\
(**A**) Volcano plot of differentially abundant proteins between wild type and *trm5-1*. In *trm5-1*, proteins that were increased in abundance are represented as blue dots, proteins decreased in abundance as red dots, with threshold fold change \> 1.2 or \< 0.83 (increased or decreased) and *P*-value \< 0.05. There were 102 proteins increased and 161 proteins decreased in *trm5-1*. (**B**) GO and (**C**) KEGG terms enrichment analysis. Each differentially abundant protein was first annotated in the GO or KEGG databases, enrichment analysis was performed based on annotated differentially expressed proteins in wild type and *trm5-1*. The top 20 enriched GO terms from Biological Processes (BP), Molecular function (MF), and Cellular Component (CC) are reported.](pone.0225064.g007){#pone.0225064.g007}

Defects in tRNA m^1^G methylation can be expected to affect mRNA translation, particularly of proteins that have high numbers of affected codons. Therefore, we were interested in identifying genes that showed reduced expression at the protein level in our proteomics analysis of *trm5* plants, but no detectable reduction in mRNA abundance. To identify such mRNAs, we performed RNA-seq on wild type and *trm5* plants. We identified 1186 transcripts that were reduced in abundance in *trm5* and 580 transcripts that were increased in abundance by at least 2-fold and hierarchically clustered these transcripts ([S2 Table](#pone.0225064.s002){ref-type="supplementary-material"} and [S5 Fig](#pone.0225064.s005){ref-type="supplementary-material"}). Comparison of the RNA-seq and proteomics datasets identified 133 proteins with reduced abundance, but with no detectable reduction in mRNA abundance ([S5 Fig](#pone.0225064.s005){ref-type="supplementary-material"}). We further inspected the data by selecting four candidate proteins with the highest fold change reported in the proteomics data ([Table 1](#pone.0225064.t001){ref-type="table"}). From the selected candidate proteins, we discovered that three of the differentially expressed proteins reported in the proteomics data were not differentially expressed in the RNA-seq data, indicating that there is no change in transcripts levels leading to the fluctuation of their corresponding proteins. Only one protein candidate (AT2G45180.1**)** showed decreased fold change of mRNA, which correlates with the decrease of its corresponding protein reported in the proteomics data.

10.1371/journal.pone.0225064.t001

###### Comparison between RNA-seq data and proteomics data of selected protein candidates.

![](pone.0225064.t001){#pone.0225064.t001g}

  Gene ID       Protein                                                                                     log2FC   Status                                   
  ------------- ------------------------------------------------------------------------------------------- -------- --------- ------------------------------ ---------------
  AT1G03540.1   Pentatricopeptide repeat (PPR-like) superfamily protein                                     N/A      3.12815   non-differentially expressed   upregulated
  AT2G45180.1   Bifunctional inhibitor/lipid-transfer protein/seed storage 2S albumin superfamily protein   2.012    0.56136   downregulated                  downregulated
  AT2G39480.1   P-glycoprotein 6                                                                            N/A      0.43734   non-differentially expressed   downregulated
  AT5G50160.1   ferric reduction oxidase 8                                                                  N/A      0.40435   non-differentially expressed   downregulated

Four protein candidates with the highest fold change (*p-value* \< 0.05) reported in the proteomics data were selected for further comparison.

Finally, we performed a codon usage frequency analysis for this class of genes and detected no codon bias towards triplets read by both m^1^I and m^1^G modified tRNAs ([S5 Fig](#pone.0225064.s005){ref-type="supplementary-material"}).

Modifications at position 37 affects tRNA-halve abundance {#sec010}
---------------------------------------------------------

Since our previous results showed no bias towards codon usage in *Attrm5* mutants when compared to wild type, we then asked if depleting m^1^G37 and m^1^I37 affects tRNA abundance. To test this, we performed a northern blot analysis on the AtTRM5 substrates tRNA-Ala-(AGC) and tRNA-Asp-(GTC), respectively ([Fig 8A](#pone.0225064.g008){ref-type="fig"}). We did not observe any substantial change in the full-length tRNA abundances for both tRNA-Ala-(AGC) and tRNA-Asp-(GTC). However, we unexpectedly observed significant decreases in the 5' half abundance of both tRNA-Ala-(AGC) and tRNA-Asp-(GTC) ([Fig 8A](#pone.0225064.g008){ref-type="fig"}), suggesting that the loss of m^1^G37 and m^1^I37 affects tRNA halve steady state abundance.

![Loss of function of AtTRM5 affects tRNA halve abundance.\
(**A**) Northern blot analysis of RNA from wild type, *trm5-1* and *35S*:*TRM5 trm5-1*. tRNA-Ala (AGC) was inspected for changes in m^1^G37 and tRNA-Asp (GTC) and m^1^I37. tRNA-Arg (CCT) and rRNA were used as loading controls. The blots were probed with either tRNA-Arg (CCT), tRNA-Asp (GTC), or tRNA-Ala (AGC). (**B**) Accumulation and aminoacylation of tRNA-Ala (AGC) in wild-type plants, *trm5-1* mutant plants and 35S:*TRM5 trm5-1*. The aminoacylated tRNA migrates slower than its corresponding deacylated species. To visualize the difference in electrophoretic mobility, aliquots of the same samples were deacylated *in vitro*. 10 μg of RNA was separated by electrophoresis, blotted and hybridized to a tRNA-Ala (AGC)-specific probe. The 25S rRNA band of the ethidium bromide-stained gel prior to blotting is shown as a loading control.](pone.0225064.g008){#pone.0225064.g008}

The anticodon region of tRNAs are known to impact tRNA aminoacylation as it interacts with tRNA aminoacyl synthetase \[[@pone.0225064.ref040]\] and that tRNA position 37 at the 3' anticodon region has a significant role in facilitating tRNA structure fidelity and anticodon interactions \[[@pone.0225064.ref020]\]. Therefore, we investigated if the tRNA position 37 which is proximal to the 3' anticodon could affect tRNA aminoacylation for tRNA-Ala-(AGC). We performed a tRNA aminoacylation experiment to determine if the loss of m^1^G37 modification at the anticodon region of tRNA-Ala-(AGC) affects tRNA charging ([Fig 8B](#pone.0225064.g008){ref-type="fig"}) and our results show that the loss of function of *AtTRM5* does not affect acylation of tRNA-Ala ([Fig 8B](#pone.0225064.g008){ref-type="fig"}). One explanation for this observation can be attributed to the nature of alanyl-tRNA synthetases that recognizes G3:U70 of tRNA acceptor stem for tRNA charging instead of the anticodon region \[[@pone.0225064.ref041]\]. This showed that the loss of m^1^G37 modification does not inhibit aminoacylation.

Discussion {#sec011}
==========

The discovery of m^1^G and m^1^I at position 37 in tRNAs of a wide range of eukaryotic and prokaryotic organisms underscores its importance as a key regulator of tRNA function and, presumably, translation \[[@pone.0225064.ref010], [@pone.0225064.ref021], [@pone.0225064.ref023]\]. Previous studies in bacteria have shown that m^1^G37 is required for translational fidelity \[[@pone.0225064.ref021], [@pone.0225064.ref042], [@pone.0225064.ref043]\] and that mutations in the enzymes catalysing m^1^G37 severely impact growth or cause lethal phenotypes \[[@pone.0225064.ref010], [@pone.0225064.ref023], [@pone.0225064.ref031]\]. The presence of m^1^G37 modification on tRNA-Asp prevents erroneous amino-acylation by arginyl-tRNA synthetase as both tRNA-Asp and tRNA-Arg have highly similar structures \[[@pone.0225064.ref044]\].

In eukaryotes, m^1^G37 modification requires the methyltransferase TRM5. Here we report that in plants, *trm5* mutants have a 60% reduction in m^1^G and m^1^I levels, display severely reduced growth and delayed transition to flowering. This is somewhat similar to human patients that are heterozygous for one mutant and one functional allele of *Trm5*. They show childhood failure to thrive and exercise intolerance symptoms \[[@pone.0225064.ref010]\].

With the 60% reduction of m^1^G and 75% reduction of m^1^I in *trm5* plants, it is reasonable to anticipate a significant impact on protein translation due to the reduced stacking effect of m^1^G37 on base-pairing between position 36 and the first nucleoside in translated mRNA codons. We observed a reduction in abundance of proteins involved in ribosome biogenesis and photosynthesis, and this is likely to account for the observed reduced growth of the mutant plants. A similar study by Jin *et al*. (2019) showed higher levels of polysomes in *attrm5a* mutants compared to wild type and decreased levels of ribosomal subunit, which is anticipated to reduce translation rate \[[@pone.0225064.ref045]\]. In the future, it would be interesting to test if translational errors, such as ribosome stalling or frame shifting, occur in *trm5* plants which would be similar to what has been previously reported in bacteria with reduced tRNA m^1^G \[[@pone.0225064.ref026]\].

We localized *Arabidopsis* TRM5 to the nucleus which is in contrast to the cytoplasmic and mitochondrial localisation in other eukaryotes: *Trypanosoma brucei*, *Homo sapiens* (HeLa cells) and *Saccharomyces cerevisiae* \[[@pone.0225064.ref010], [@pone.0225064.ref023], [@pone.0225064.ref031]\], although in one study *S*. *cerevisiae* Trm5 has also been localized exclusively to the nucleus \[[@pone.0225064.ref036]\]. Interestingly, in yeast, Trm5 acts in the nucleus to form m^1^G on retrograde imported tRNA^Phe^ after initial export from the nucleus and subsequent splicing at the mitochondrial outer membrane. As retrograde tRNA import is conserved from yeast to vertebrates \[[@pone.0225064.ref046], [@pone.0225064.ref047]\], it is tempting to speculate that TRM5-mediated m^1^G formation occurs in retrograde imported tRNAs in *Arabidopsis*.

Direct comparison of RNA-seq and proteomics data has been challenging as variation in protein abundance in proteomics datasets can be confounded by multiple factors. Several factors can cause fluctuation in protein levels with no change of mRNA abundance: mRNA transcript abundance, translation rate, and translation resources availability (as reviewed in Liu, Beyer (48)). This may explain the results of the initial comparison between our RNA-seq and proteomics data, and the seeming discrepancies in the derived sets of differentially expressed genes ([S2](#pone.0225064.s007){ref-type="supplementary-material"} and [S3](#pone.0225064.s008){ref-type="supplementary-material"} Tables). In our RNA-seq data, microtubule-related genes appeared to be significantly downregulated (AT1G21810, AT1G52410, AT2G28620, AT2G44190, AT3G23670, AT3G60840, AT3G63670, AT5G67270, AT4G14150, AT5G27000). However, we could not detect any differential expression of these proteins in our proteomics dataset. This is not unexpected, as it has been reported that protein and transcript abundances only rarely correlate in data analysis \[[@pone.0225064.ref048]\]. However, it has been shown that transcript abundance can still be used to infer protein abundance \[[@pone.0225064.ref049]\]. Among the selected four candidate proteins ([Table 1](#pone.0225064.t001){ref-type="table"}), we could observe only one event of protein downregulation due to decreased transcript level: the lipid transfer protein (AT2G45180) which is involved in lipid transport in chloroplasts. Lipid transport is crucial in the formation of photosynthetic membranes in plants \[[@pone.0225064.ref050]\]. As several lipids are important functional components of thylakoidal protein complexes involved in photosynthesis, the impacted lipid transport and lipid synthesis revealed by the GO term analysis may contribute to the observed dysregulation of photosynthesis-related genes. This finding is consistent with Jin *et al*. (2019) \[[@pone.0225064.ref045]\]. The remaining three candidate genes displayed no changes in transcript levels, but one candidate gene showed upregulation and the other two downregulation at the protein level. The exact function of pentatricopeptide repeat (PPR-like) superfamily protein (AT1G03540.1) is unknown, but the protein was suggested to play a significant role in post-transcriptional modification of tRNAs \[[@pone.0225064.ref051]\]. The P-glycoprotein 6 (AT2G39480) belongs to the large P-glycoprotein family and is known to play a role in mediating auxin transport, and disturbed auxin transport is known to affect plant growth \[[@pone.0225064.ref052]\]. Our proteomics data suggested that the auxin transport is affected (AT5G35735, AT3G07390, AT4G12980, AT5G35735) in the *trm5* mutant. This can be inferred to the reduced auxin levels in *attrm5a* as reported by Jin *et al*. (2019) \[[@pone.0225064.ref045]\]. Ferric reduction oxidase 8 (AT5G50160/AtFRO8) has been shown to participate in iron reduction and was implicated in leaf vein transport \[[@pone.0225064.ref053]\]. We proposed that disturbed photosynthesis in *trm5* mutant plants is a secondary effect of dysregulated transport processes.

Our findings also show that modified bases at tRNA-Ala at position 37 does not affect tRNA aminoacylation but does affect tRNA-Ala-derived 5' half steady state abundance. Both tRNA aminoacylation and tRNA-derived halves were shown to effect translational fidelity \[[@pone.0225064.ref040], [@pone.0225064.ref054]\]. In yeast, the introduction of tRNA-derived halves, both 5' and 3' fragments, affects tRNA aminoacylation, suggesting that tRNA-derived fragments (tRFs) has a regulatory role in translation \[[@pone.0225064.ref054]\]. It was also demonstrated that these tRFs regulate tRNA-aminoacylation via interacting with ribosome. The decreased amount of tRNA-Ala 5' halves may explain the polysome profile changes reported by Jin *et al*. (2019) \[[@pone.0225064.ref045]\].

The role of post-transcriptional RNA modifications in tRNA and mRNA metabolism and their impact on plant growth and development in plants are only beginning to be elucidated. Here, we have described the AtTRM5-mediated m^1^G and m^1^I methylation in tRNAs and identified crucial links between this modification, photosynthesis, plant growth, and protein translation. It appears likely that the many other tRNA modifications in plant tRNAs also play important roles in translation and/or translational regulation which remain to be discovered.

Materials and methods {#sec012}
=====================

Plant material and root growth experiments {#sec013}
------------------------------------------

*Arabidopsis thaliana* (Columbia accession) wild type and mutant plants were grown in Phoenix Biosystems growth under metal halide lights as previously described \[[@pone.0225064.ref055]\]. For plate experiments, seeds were first surface sterilized, plated on ½ MS medium supplemented with 1% sucrose and sealed as previously described \[[@pone.0225064.ref001], [@pone.0225064.ref056]\]. All plants were grown under either long-day photoperiod conditions of 16 h light and 8 h darkness or short-day photoperiods of 10 h light and 14 h darkness.

Characterization of the mutant alleles, *trm5-1* (SALK_022617) and *trm5-2* (SALK_032376) are as described previously \[[@pone.0225064.ref057]\]. The *tad1-2* mutant was used as described previously \[[@pone.0225064.ref011]\]. Nucleotide sequence data for the following genes are available from The *Arabidopsis* Information Resource (TAIR) database under the following accession numbers: TRM5 (At3g56120), At4g27340, At4g04670, and TAD1 (At1g01760).

Analysis of root phenotypes was carried out on 11-day-old seedlings grown on ½ MS agar plates. A flatbed scanner (Epson) was used to non-destructively acquire images of seedling roots grown on the agar surface. Once captured, the images were analysed by software package RootNav \[[@pone.0225064.ref058], [@pone.0225064.ref059]\].

Plasmid construction and generation of transgenic plants {#sec014}
--------------------------------------------------------

For the 35SCaMV:TRM5 construct, the full-length genomic region of At3g56120 including the 5'UTR and 3'UTR was amplified from Col-0 genomic DNA template with primers provided in ([S1 Table](#pone.0225064.s006){ref-type="supplementary-material"}) and cloned into Gateway entry vector pENTRTM/SD/D-TOPO (Invitrogen). The insert was sequenced and then cloned into the binary destination vector pGWB5 by an LR recombination reaction, using the Gateway cloning system following the manufacturers protocol (Invitrogen), resulting in the 35S:TRM5 construct. For the TRM5~Pro~::TRM5 construct, the full-length genomic region of At3g56120 that included the promoter, 5'UTR and 3'UTR was amplified from Col-0 genomic DNA template with primers provided in ([S1 Table](#pone.0225064.s006){ref-type="supplementary-material"}) and cloned into Gateway entry vector PCR8 TOPO-TA (Invitrogen). The insert was sequenced and then cloned into the a modified (35S promoter removed) destination pMDC32 vector, using the Gateway cloning system \[[@pone.0225064.ref060]\] following the manufacturers protocol (Invitrogen), resulting in TRM5~Pro~::TRM5. The 35S:TRM5 construct was transformed into *A*. *thaliana* wild type Col-0 plants or *trm5-1* mutant plants by *Agrobacterium*-mediated floral dip method respectively \[[@pone.0225064.ref061]\]. The TRM5~Pro~::TRM5 construct was transformed into *trm5-2* mutant plants by *Agrobacterium*-mediated floral dip method. Transgenic plants were selected on ½ MS media supplemented with 50 μg ml^-1^ kanamycin. TRM5 transcript abundance was assessed in at least five independent T~1~ plants using qRT-PCR and two lines showing the highest TRM5 transcript levels were carried through to homozygous T~3~ generation for phenotypic analysis.

Sub-cellular localization of TRM5 {#sec015}
---------------------------------

For analysis of subcellular localization of TRM5, a 35S:TRM5:GFP construct was produced by PCR amplification of the TRM5 coding sequence from *Arabidopsis* seedling cDNA by using the primers described in the supplementary data ([S1 Table](#pone.0225064.s006){ref-type="supplementary-material"}). The TRM5 cDNA was recombined cloned into pCR8, sequenced and then recombined in frame into pMDC83 to produce 35S:TRM5:GFP. The 35S:TRM5:GFP construct was introduced into *A*. *tumefaciens* strain GV3101 and transiently expressed in 5-week-old *Nicotiana benthamiana* leaves. Fluorescence was analysed using a confocal laser-scanning microscope (Zeiss microscope, LSM700) and excited with 488-nm line of an argon ion laser. GFP fluorescence was detected via a 505- to 530-nm band-pass filter. The cut leaves were immersed in 10 μM 4ˊ, 6-diamidino-2-phenylindole (DAPI) at room temperature for 45 min, and then washed with PBS for 3 times (5 min each). The blue fluorescence of DAPI was imaged using 404-nm line for excitation and a 435- to 485-nm band pass filter for emission.

Shoot apical meristem sections {#sec016}
------------------------------

14, 18, or 22-day-old seedlings were fixed for 1 day in FAA containing 50% ethanol, 5% acetic acid and 3.7% formaldehyde. The samples were then dehydrated through an ethanol series of five one-hour steps (50, 60, 70, 85, 95% ethanol) ending in absolute ethanol (100%). The ethanol was gradually replaced with Histoclear containing safranine to stain the tissue, as following: incubated in a Histoclear series (75:25, 50:50, 25:75 Ethanol: Histoclear) for 30 min and followed by twice one-hour incubation in 100% Histoclear. The paraffin was polymerised by baking overnight at 60°C, and the samples were embedded in paraffin. Sections were cut, attached to slides and dried on a slide warmer overnight at 42°C to allow complete fixation. The shoot apical meristem was observed using light microscopy.

Quantitative real-time PCR (qPCR) {#sec017}
---------------------------------

For the transcription profiling of flowering-related genes and circadian clock-related genes, 17-day-old seedlings were sampled from Zeitgeber time (ZT) 1 and collected every 3h during the day and night cycles, respectively. Total RNA was extracted the leaf samples using Trizol reagent (Invitrogen). The relative expression levels of *AtTRM5* were determined using quantitative real-time PCR (qPCR) with gene-specific primers ([S1 Table](#pone.0225064.s006){ref-type="supplementary-material"}). The qPCR was performed using the StepOnePlus real-time PCR system (Applied Biosystems) using Absolute SYBR Green ROX mix (Applied Biosystems) for quantification. Three biological replicates were carried out for each sample set. The relative expression was corrected using a reference gene *EF1alpha* (At5g60390) and calculated using the 2^--ΔΔCq^ method as described previously \[[@pone.0225064.ref011]\].

mRNA-sequencing {#sec018}
---------------

Total RNA, 1 ug, was extracted from 20-day-old *Arabidopsis* leaf samples using Trizol reagent (Invitrogen) and purified using the RNAeasy Mini RNA kit (Qiagen). One hundred nanograms of RNA were used for RNA-seq library construction according the manufacturer's recommendations (Illumina). First-strand cDNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen). After second strand cDNA synthesis and adaptor ligation, cDNA fragments were enriched, purified and then sequenced on the Illumina Hiseq X Ten. Three biological replicates were used for RNA-seq experiments.

tRNA purification and tRNA-sequencing {#sec019}
-------------------------------------

Total RNA was isolated from wild type and *trm5* 10-day-old *Arabidopsis* seedlings using the Spectrum Plant total RNA kit (SIGMA-ALDRICH) and contaminating DNA removed using DNase I (SIGMA-ALDRICH). To enrich for tRNAs, 10μg of total RNA was separated on a 10% polyacrylamide gel, the region containing 65--85 nts was removed and RNA was purified as previously described \[[@pone.0225064.ref056]\]. Purified tRNAs were used for library construction using NEB Ultradirectional RNA library kit. Given the short sequences of tRNAs, the fragmentation step of the library preparation was omitted, and samples were quickly processed for first-strand cDNA synthesis after the addition of the fragmentation buffer. The remaining steps of library construction were performed as per the manufacturer's instructions. Illumina sequencing was performed on a MiSeq platform at The Australian Cancer Research Foundation (ACRF) Cancer Genomics Facility, Adelaide.

Yeast complementation {#sec020}
---------------------

AtTrm5 (At3g56120) and ScTrm5 (YHR070W) was PCR amplified from cDNA and cloned into pYE19 using a Gibson assembly reaction (NEB). Mutant AtTrm5 (R166D) was generated by synthesising gene blocks (IDT) with nucleotides that mutated the translated proteins at R166 and the gene block was cloned into pYE19 using a Gibson assembly reaction (NEB). Yeast △trm5 (*Mat a*, *hisD1*, *leu2D1*, *met15D0*, *trm5*:*KanMX)* was previously described \[[@pone.0225064.ref062]\]. Recombinant plasmids were transformed into △*trm5* mutant strain and the resulting strain was analysed for growth phenotypes and m^1^G nucleoside levels.

AtTrm5, AtTAD1, ScTrm5 protein expression and purification and tRNA methylation {#sec021}
-------------------------------------------------------------------------------

Full length AtTrm5, mutant AtTrm5 (R166D) and AtTAD1 (At1g01760) cDNAs were cloned into pGEX resulting in GST-AtTrm5, GST-AtTRM5-mutant, GST-TAD1, respectively. Mutant AtTAD1 (E76S) was generated by synthesising a gene block (IDT) with mutated nucleotides and the gene block was cloned into pGEX using a Gibson assembly reaction (NEB) resulting in GST-TAD1 mutant. IPTG (0.5 μM) was used to induce expression of the proteins and the recombinant proteins were purified on a GST resin column (ThermoFisher Scientific). tRNA-Asp-GUC or tRNA-Ala-AGC were transcribed in vitro with T7 RNA polymerase (Promega). Methylation reactions were performed in 100 mM Tris-HCl, 5 mM MgCl~2~, 100 mM KCl, 2 mM DTT, 50 mM EDTA, 0.03 mg/mL BSA and 25 μM AdoMet. Substrate tRNA was provided in a final concentration of 1--5 μM, AtTrm5 or AtTrm5 mutant proteins from 6.0 to 12 μM and AtTAD1 or AtTAD1 mutant proteins at 5.0 μM.

mRNA-seq and tRNA-seq bioinformatics analysis {#sec022}
---------------------------------------------

Global Mapping: Reads were first adapter trimmed using Trim galore v0.4.2 (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>) with default parameter. The quality of the trimmed reads was checked using Fastqc (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and ngsReports (<https://github.com/UofABioinformaticsHub/ngsReports>). Reads were then globally mapped to *Arabidopsis* reference genomes (TAIR10) \[[@pone.0225064.ref063]\] using STAR v2.5.3 \[[@pone.0225064.ref064]\]. Mapped reads were counted using featureCounts \[[@pone.0225064.ref065]\]. The raw read counts were normalized using sample size factor for sequence depth and differential expression analysis between wild type and *trm5-1* mutant samples was performed using DESeq2 v1.18.1 \[[@pone.0225064.ref066]\]. The tRNA-enriched reads were mapped to tDNA reference acquired from GtRNAdb (generated from tRNA-Scan SE v2.0) of *Arabidopsis thaliana* derived from TAIR10 reference genome \[[@pone.0225064.ref063], [@pone.0225064.ref067]--[@pone.0225064.ref069]\] using segemehl v0.2.0 \[[@pone.0225064.ref068]\]. The mapped reads were then processed for variant calling using GATK v3.7 \[[@pone.0225064.ref070]\]. Haplotype Caller in GATK v3.7 was implied to call for variants, with the variant filtered using hard filtering as recommended.

Proportion estimation: SNPs were identified in the wild type and *trm5-1* samples were then compared. SNPs at position 37 were extracted and analysed using vcftools \[[@pone.0225064.ref071]\]. Changes in base pair modifications were indicated by base substitution due to the property of next generation sequencing as mentioned in \[[@pone.0225064.ref010], [@pone.0225064.ref035]\]. The ratio of the expected A-to-T conversion in wild type samples and both the ratio of A-to-T (indicating no change in comparison to wild type) and A-to-G in *trm5-1* were analyzed as an indication of m^1^I depletion.

Sanger sequence analysis of tRNA editing {#sec023}
----------------------------------------

tRNA purification and tRNA editing analysis were performed as described previously \[[@pone.0225064.ref011]\]. Cytosolic tRNA-Ala (AGC) were amplified by reverse transcriptase (RT)-PCR with specific primers (tRNA-Ala-f and tRNA-Ala-r, [S1 Table](#pone.0225064.s006){ref-type="supplementary-material"}), and purified PCR products were directly Sanger sequenced.

TMT-based proteome determination and data analysis {#sec024}
--------------------------------------------------

Total protein was extracted from 20-day-old *Arabidopsis* leaf samples and purified according to a method described by \[[@pone.0225064.ref072]\]. Protein digestion was performed according to FASP procedure described previously \[[@pone.0225064.ref073]\], and 100 ųg peptide mixture of each sample was labelled using TMT reagent according to the manufacturer's instructions (Thermo Fisher Scientific). LC-MS/MS analysis was performed on a Q Exactive mass spectrometer (Thermo Fisher Scientific) that was coupled to Easy nLC (Thermo Fisher Scientific). MS data was acquired using a data-dependent top20 method dynamically choosing the most abundant precursor ions from the survey scan (200--1800 m/z) for HCD fragmentation (Shanghai Applied Protein Technology Co., Ltd). Determination of the target value is based on predictive Automatic Gain Control (pAGC). SEQUEST HT search engine configured with Proteome Discoverer 1.4 workflow (Thermo Fisher Scientific) was used for mass spectrometer data analyses. The latest *Arabidopsis* protein databases (2018) was downloaded from <http://www.arabidopsis.org/download/index-auto.jsp?dir=/download_files/Proteins> and configured with SEQUEST HT for searching the datasets. The following screening criteria was deemed as differentially expression: fold-changes \>1.2 or \<0.83 (up- or down-regulation) and the Benjamini-Hochberg corrected *p*-value, *P* \< 0.05 were considered significant.

tRNA nucleoside analysis {#sec025}
------------------------

tRNAs were purified as previously described \[[@pone.0225064.ref056]\]. Twenty-five μg of tRNAs were digested with P1 nuclease (Sigma- Aldrich) and 1.75 units of calf intestine alkaline phosphatase in 20 mM Hepes--KOH (pH 7.0) at 37°C for 3 h. The mixture was diluted to a concentration of 15 ng/uL and samples were injected into an API 4000 Q-Trap (ThermoFisher Scientific) mass spectrometer coupled with LC-20A HPLC system (Shimadzu). All RNA samples analyzed were from three biological replicates. A diode array UV detector monitored the LC signals from the nucleosides, whereas in counts were recorded in positive mode (190−400 nm). The abundance of each modified nucleoside was represented by its unique ion peak area and normalized to the sum of the four canonical nucleosides (A, C, G and U nucleosides). Since m^1^G, m^2^G and m^7^G have the same Q1 and Q3 mass, they were discriminated by retention time, in the order of m^7^G, m^1^G and m^2^G, respectively. The identity of m^7^G peak was confirmed with external standard (TriLink Biotechnologies) and the identity of m^1^G versus m^2^G was indirectly confirmed by results from yeast *trm5* mutant

Northern blot for tRNA detection {#sec026}
--------------------------------

Total RNA was isolated from the wild type, *trm5-1* and *35S*:*TRM5 trm5-1 Arabidopsis* seedlings by using the TRIZOL Reagent (ThermoFisher Scientific). 20μg of total RNA was on 15% urea-polyacrylamide gel and RNA was transferred to Amersham Hybond-N^+^membrane. After cross-linking, prehybridization was performed for 3 hours at 68°C in 20μl of DIG easy Hyb Granules (Roche). 60 pmol of 3-end Digoxin labelled oligonucleotides was added to hybridization buffer ([S1 Table](#pone.0225064.s006){ref-type="supplementary-material"}) and hybridize for overnight at 40°C with gentle agitation. The membrane was washed at low-stringency (2X SSC, 0.1% SDS) twice and high-stringency (0.1X SSC, 0.1% SDS) twice. The probe-target hybrid was localised with the anti-DIG-alkaline phosphatase antibody (Roche), and the membrane was put into washing and blocking and detection buffer to visualize using the CDP-Star, ready to use (Roche).

tRNA aminoacylation assay {#sec027}
-------------------------

Total RNA of wild type, *trm5-1* and *35S*:*TRM5 trm5-1 Arabidopsis* seedlings were isolated and analysed using the tRNA aminoacylation protocol as described in Zhou, Karcher (11), using a specific probe for tRNA-Ala (AGC) ([S1 Table](#pone.0225064.s006){ref-type="supplementary-material"}).

Supporting information {#sec028}
======================

###### Extended phylogenetic analysis of TRM5 orthologues.

(**A**) Circos plot of sequence conservation of TRM5 orthologues in yeast (Sc), tomato (Sl), grape (Vv), *Arabidopsis* (At), maize (Zm), rice (Os), *Marchantia* (Mp), *Physcomitrella* (Pp), *Chlamydomonas* (Cr),*Ostreococcus* (Ot), humans (HsTrm5), *Drosophila melanogaster* (DmTrm5), *Pyrococcus horikoshii* (PhTYW2), and *Methanococcus jannaschii* (MjTYW2). The ribbons were coloured based on sequence identity, with blue \< = 25%, green 25--50%, orange 51--75% and red for 76--99%. (**B**) Unrooted phylogenetic tree of the same TRM5 orthologues used to for sequence conservation analysis.

(TIF)

###### 

Click here for additional data file.

###### Bioinformatics characterization of TRM5 and related proteins.

(**A**) Multiple sequence alignment of TRM5 proteins from *Arabidopsis thaliana* (At), yeast (ScTrm5), humans (HsTrm5), *Drosophila melanogaster* (DmTrm5), *Pyrococcus horikoshii* (PhTYW2), and *Methanococcus jannaschii* (MjTYW2). Black shaded boxes are identical across all species. Light shaded boxes are similar and nearly conserved residues. Asterisk indicates catalytic important amino acids. The predicted 29 aa importin α-dependent NLS is boxed in red. (**B**) Multiple sequence alignment of yeast Trm5p, *Arabidopsis* TRM5 (At3g56120) and the two closest related proteins from *Arabidopsis*. Black shaded boxes are conserved in at least 2 sequences. Met 10+ like domain and S-adenosyl Methyltransferase Motif (SAM) are detected in *Arabidopsis* TRM5 using NCBI Conserved Domains Search (<https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi>). The position of importin α-dependent NLS is also indicated.

(TIF)

###### 

Click here for additional data file.

###### Characterisation of growth and development in wild type, trm5 mutant, complemented and overexpression lines.

(**A**) Seeds (n = 100) of wild type and *trm5-1* were sown on ½ MS plates, stratified at 4 ^o^C and then grown at 21 ^o^C under long day conditions for 32 hours. Germination was measured at 8, 16, 24 and 32 hours after shifting to 21 ^o^C. (**B**) Sections of the shoot apical meristems of wild type and *trm5-1* plants grown under long days for 14, 18 and 22 days. (**C**) The average fresh plant weight of long day grown plants. (**D**) The average rosette leaf number at flowering; (**E**) The average days to flowering under long days. (**F**) The rosette leaf number under short days. Data presented are means. Error bars are ± SE (n = 16). NF = did not flower. An asterisk indicates a statistical difference (*P*\<0.05) as determined by Student's t-test.

(TIF)

###### 

Click here for additional data file.

###### Root phenotypic analysis of seedlings.

Seedlings of wild type, *trm5*, complemented lines (35S:TRM5 *trm5-1*), TRM5 overexpression lines (35S:TRM5) were vertically grown on ½ MS medium for 10 days and then measured. (**A**) Total root length, (**B**) Primary root, (PR) length, (**C**) average lateral root (LR) length and (**D**) LR number were measured 10 days after germination. Data presented are means. Error bars are ± SE (n = 10 plants).

(TIF)

###### 

Click here for additional data file.

###### RNA-seq and proteomic analysis of wild type and trm5-1.

(**A**) RNA was purified from 10-day-old seedlings of wild type (wt) and *trm5-1* (n = 3). RNA-seq analysis was performed and differentially abundant transcripts were hierarchically clustered. (**B**) An upset plot showing positive overlapping mRNAs and proteins identified by RNA-seq and proteomics analysis. (**C**) Codon bias analysis of codons in the up and down regulated proteins identified by proteomics analysis.

(TIF)

###### 

Click here for additional data file.

###### Oligonucleotide primers used in this study.

(DOCX)

###### 

Click here for additional data file.

###### Differentially expressed genes identified by RNA-seq analysis of wild type and *trm5-1*.

(XLSX)

###### 

Click here for additional data file.

###### Differentially abundant proteins identified by LC-MS/MS analysis of wild type and *trm5-1*.

(XLSX)

###### 

Click here for additional data file.
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PLOS ONE

Dear Dr Searle,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your manuscript has been evaluated by two experts in the field. While their comments are in general positive, they have also raised a number of points that need to be fixed and/or clarified (e.g. by giving additional details of your experimental and data analysis protocols) before your manuscript can be accepted for publication in PLOS ONE. I have also taken the time to read your manuscript carefully, and my understanding is that most of those points are relatively easy to address, either in the main body of your manuscript or in the rebuttal letter, as appropriate.

I understand that you want to keep the focus of your work on only one of the three paralogous genes, and I am not asking you to perform additional experiments regarding this. However, please make sure to temper your conclusions, as suggested by reviewer \#2 in point \#1 of his/her evaluation report. This reviewer has also pointed out that some of your data have not been made available (i.e. Figure S6); please make sure that all figures and other data supporting your conclusions are available in the revised version, in line with the journal\'s policy on data availability.

We would appreciate receiving your revised manuscript by Sep 26 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Hector Candela, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

2\. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors' affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating "current affiliation:...." as necessary).

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript (PONE-D-19-17540) reports the characterization of Arabidopsis TRM5 and the growth phenotype of Arabidopsis trm5 gene disruptant strain. TRM5 is a tRNA methyltransferase, which methylates G37 and I37 in tRNA, and produces m1G37 and m1I37, respectively. As described in this manuscript, there are little knowledges about tRNA modification enzymes in plant. Although Jin et al. reported similar characterization of Arabidopsis TRM5 during the course of study by the authors, I believe that this manuscript contains several scientific merits to be published in the journal "PLOS ONE". Before the publication, however, I would like to suggest some minor revisions.

Minor points:

\(1\) Page 6 lines 139-143.

As far as I know, m1I is found only at position 37 in tRNAs from eukaryotes.

However, m1I in tRNAs from trm5 mutants is not lost completely. I feel that some explanations for this observation may be necessary.

\(2\) Page 3 lines 58-59: "....in plants and animals, .......modified cellular RNAs \[6-9\]."

The references 6-9 describe not only modifications in plants and animals but also those in microorganisms. Please alter the sentence.

\(3\) Page 3 lines 74-75: ".... To maintain translational fidelity and efficiency \[10, 19, 20\]."

As the authors know, the most basic function of m1G37 modification in tRNA is prevention of frameshift error. The reference 24 should be cited in this sentence.

\(4\) The m1G37 modification may prevent erroneous amino-acylation of tRNAAsp by Arg-RS. See this reference "Perret et al. Nature 344, 787-789 (1990)".

\(5\) Please check the citations through the manuscript. For example, Page 4 line 94: the reference \[26\] may be \[27\]. Page 4 line 81: Why do the authors cite the reference \[27\] in this sentence? Comparison of Trm5 and TrmD is summarized in this review "Hori Biomolecules 7, 23 (2017)".

\(6\) The abbreviations of tRNAs should be unified. For example, Page 4 line 86: "tRNAPRO and tRNALEU" should be "tRNAPro and tRNALeu". Figure 4C: "tRNAASP" should be "tRNAAsp".

\(7\) Page 5 line 109: the words "Attrm5 plant". To prevent misunderstanding by the readers, "Attrm5 mutant plant" is recommended.

\(8\) Page 5 line 117: "Pyrococcus, and Methanococcus". Please use italic fonts.

\(9\) Page 9 line 198: "mutant Attrm5 R166D". Is this a gene name? If so, the words "a catalytic inactive" may be not appropriate.

\(10\) Page 9 line 212: "T7 polymerase" -\> "T7 RNA polymerase".

\(11\) Page 10 line 242: "S-adenosyl-methionine (AdoMet)". These words have already been described in Page 9 line 214.

\(12\) Page 13 line 313: "KEGG annotation revealed enrichment of proteins involved in photosynthesis, and photosynthetic proteins". If possible, please add information whether the genes for these proteins are encoded in the nucleus genome. This information may help discussions in Page 17-18.

\(13\) Page 15 line 353: "suggesting that the loss of m1G37 and m1I37 affects tRNA half stability". The results in Figure 8 do not show the stability of tRNA half directly. Please revise the sentence.

Page 18 line 438: "....5' half stability". Please revise the sentence by the same reason.

\(14\) Page 15 line 355-364. In general, Ala-RS does not recognize the anticodon-loop. Therefore, the results by the authors seem to be reasonable. Please see this paper "Chong et al. Proc. Natl. Acad. Sci. USA 115, 7527-7532 (2018)".

\(15\) Page 16 line 373: "a 60% reduction in m1G and m1I levels". The reduction in m1I level may be not 60%.

\(16\) Page 24 line 575: "T7 polymerase" -\> "T7 RNA polymerase"

Reviewer \#2: The manuscript describes the analysis of the A. thaliana homolog of the TRM5 tRNA methyltransferase, using biochemical and genetic approaches. The data provided strongly support the conclusion that the studied homolog (AtTRM5) is a bonafide m1G37 methyltransferase, by decreased m1G levels in mutant plants, ability of the gene to complement the yeast trm5delta mutant phenotype, and apparent m1G modification activity on a yeast tRNA in the presence of the purified enzyme. These data are all relatively sound (although a few technical issues should be addressed as described below), and therefore are consistent with the expected function of this enzyme. Likewise, the identification of several phenotypes associated with mutant plants are intriguing, and were identified through well-controlled experiments, including complementation by re-expressing the wild-type enzyme in the mutant strains. Again, these data support the conclusion that there is an important function for Trm5 and its methylation activity. Where the paper falls significantly short, however, is in a very limited description of some experiments and methods, making it difficult to assess the data and its significance or quality. Moreover, there is a major gap left unaddressed regarding the possible significance and roles for the other two Trm5 homologs encoded by the A. thaliana genome, as discussed below.

1\) Based on the sequence alignment shown in Figure S2, it is unclear why the authors focused on this specific homolog, and not either of the other two identified genes, since conserved motifs are present in all three. Importantly, the sequence of ScTrm5 shown in figure S2B is not complete- seems to start somewhere in the middle of the protein sequence in this alignment (as opposed to S2A which shows the whole thing). The possibilities of redundant or overlapping functions, as has been now identified for many families of enzymes with similar gene duplications in multicellular eukaryotes, can not be ignored. If the authors choose not to look at these other enzymes and their activities through similar experiments, conclusions about the uniqueness or sufficiency of the studied AtTrm5 ortholog should be significantly tempered. For example, the residual m1G (\~30%) and m1I (\~10%) levels in the mutant plants were dismissed as being the result of modification at position 9, and while this is a possibility, the alternative explanation that these are the result of activity by the other proteins is not considered. The sequence alignments with the other two genes should be moved to the main results for transparency, along with addressing these issues.

2\) For the recombinant protein activity assays, it seems that levels of m1G were measured by the MS assay (although not stated in methods where activity assay is described). However, details regarding how \"relative nucleoside level\" were determined and what this means are not provided. This is significant because if the relative level of 1.0 means 100% modification of G37, then the meaning of the \~1.5X modification at higher levels of enzyme is unclear. Same is true for m1I assay results.

3\) The description of data analysis for the deep sequencing results for modification shown in figure 5C are entirely missing, and the data are not clearly presented (greatly oversimplified) because there is no quantification of the results. For this type of approach, it seems that there would have been an analysis of large numbers of reads, so it is unlikely that there was quantitative conversion of the A37 nucleotide to the T or G that is reported in the mutant strains. What were the total numbers of reads, and percentages of T substituted (and other substitutions) vs. G substituted reads from each tRNA? If there was 100% conversion in every read, then this unusual situation (even in other well-studied examples of analyzing tRNA modificaitons by RNAseq there are sequencing errors and some biological signal from unreacted substrates) should be discussed. The sanger results for the trm5-1 mutant (5D) anyway suggest that this is unlikely, since a significant A peak due to (presumably) unreacted A37 is clearly visible in the trace.

4\) The location of the GFP reporter fusion (N-or C terminal) is never identified, and description of the construct in the section about fluorescence references the previous section on cloning where GFP is never mentioned. This is relevant because GFP location could affect activity and/or localization of the protein, and certainly if a N-terminal GFP is used, it may not be able to detect mitochondrial signal, if there is one.

5\) The description of the newly identified NLS is somewhat confusing- the implication seems to be that the identified importin-dependent NLS is unique to plant Trm5, but yet it is clearly in a highly conserved part fo the enzyme including with ScTrm5?

6\) Although it is hard to read figure 7, it is unclear whether figure 7B includes only down-regulated proteins, or all differentially expressed (up and down). If includes both, some presentation of the data that supports the statement that the downregulated ones were specifically over-represented in the photosynthesis related ones is needed.

7\) Figure S6, which according to text validates the proteomics data, is missing from the manuscript I received for review. Therefore this claim can not be evaluated.

8\) It is hard to evaluate the RNAseq and proteomics results since these are not performed by ribosome profiling (more easy to internally control and standardize). Validation with northern and western for these specific targets identified in Figure S5 (some of the 27, plus some controls) would be needed to confirm. These data are better reserved for a future study in the absence of additional validation or rationalization, especially in light of the inconsistencies described extensiovely in discussion.

9\) A control northern experiment for tRNA half levels for a non-substrate tRNA (such as the tRNAArg control) is needed to evaluate the specificity of the observed loss of tRNA half abundance- is this direction due to the loss of trm5 activity, or an indirect effect of the many other phenotypes identified earlier in the paper? Without these data, the conclusions made about this in discussion are somewhat overreaching.

Editorial comments-

1\) The introduction needs proofreading and revision for clarity overall, including issues with English grammar/language.

2\) Figures are very low quality in the pdf version I got for review- should be addressed in revised version.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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8 Sep 2019

Please find below a point-by-point response to reviewers one and two comments.

Reviewer \#1

Response- We thank reviewer one for their very positive recommendation to accept out manuscript for publication after addressing the minor points raised below.

Minor points:

\(1\) Page 6 lines 139-143. As far as I know, m1I is found only at position 37 in tRNAs from eukaryotes. However, m1I in tRNAs from trm5 mutants is not lost completely. I feel that some explanations for this observation may be necessary.

Response- Edits have been incorporated as suggested, in page 6 line 159-160. The residual m1I in trm5 could be attributed to m1I found at position 57. The reference \[33\] Torres et al. 2014 "A‐to‐I editing on tRNAs: Biochemical, biological and evolutionary implications" has been added to support the statement.

\(2\) Page 3 lines 58-59: "....in plants and animals, .......modified cellular RNAs \[6-9\]." The references 6-9 describe not only modifications in plants and animals but also those in microorganisms. Please alter the sentence.

Response- The sentence has been altered to " ...mRNAs in yeast, plants, and animals" to include microorganisms as described in the references 6-9 and as suggested by the reviewer.

\(3\) Page 3 lines 74-75: ".... To maintain translational fidelity and efficiency \[10, 19, 20\]."

As the authors know, the most basic function of m1G37 modification in tRNA is prevention of frameshift error. The reference 24 should be cited in this sentence.

Response- The sentence has been edited to " ...maintain translational fidelity, prevent frameshift error, and efficiency" with the reference (previously reference \[24\]) \[21\] Björk GR et al. (1989)." Page 3 line 79. Prevention of translational frameshifting by the modified nucleoside 1-methylguanosine" included as suggested by the reviewer.

\(4\) The m1G37 modification may prevent erroneous amino-acylation of tRNAAsp by Arg-RS. See this reference "Perret et al. Nature 344, 787-789 (1990)".

Response- The suggested literature \[44\] Perret et al. (1990) "Relaxation of a transfer RNA specificity by removal of modified nucleotides" has been included in page 16 lines 404-406 to facilitate the discussion of modification m1G37.

\(5\) Please check the citations through the manuscript. For example, Page 4 line 94: the reference \[26\] may be \[27\]. Page 4 line 81: Why do the authors cite the reference \[27\] in this sentence? Comparison of Trm5 and TrmD is summarized in this review "Hori Biomolecules 7, 23 (2017)".

Response- We thank the reviewer for raising this point. The references on page 4 line 87 has been checked and edited, with the reference \[28\] (previously reference \[27\]) Noma et al.(2006) "Biosynthesis of wybutosine, a hyper-modified nucleoside in eukaryotic phenylalanine tRNA" removed and replaced by the suggested citation under reference \[27\] Hori (2017) "Transfer RNA methyltransferases with a SpoU-TrmD (SPOUT) fold and their modified nucleosides in tRNA".

On page 4 line 99, reference \[26\] Björk GR et al. (2001) "A primordial tRNA modification required for the evolution of life?" has been removed and was replaced with the reference \[28\] (previously reference \[27\]) Noma et al.(2006) "Biosynthesis of wybutosine, a hyper-modified nucleoside in eukaryotic phenylalanine tRNA" as suggested by the reviewer. All references in the manuscript were checked.

\(6\) The abbreviations of tRNAs should be unified. For example, Page 4 line 86: "tRNAPRO and tRNALEU" should be "tRNAPro and tRNALeu". Figure 4C: "tRNAASP" should be "tRNAAsp".

Response- The abbreviations for tRNA has been edited to ensure that they are unified across the manuscript. This includes the tRNA abbreviations in page 4 line 91 and Figure 4C as mentioned by the reviewer.

\(7\) Page 5 line 109: the words "Attrm5 plant". To prevent misunderstanding by the readers, "Attrm5 mutant plant" is recommended.

Response- The suggested edit has been incorporated, for example into page 5 line 116, "Attrm5 plants" has now been changed to "Attrm5 mutant plants".

\(8\) Page 5 line 117: "Pyrococcus, and Methanococcus". Please use italic fonts.

Response- Thank you. This has been accordingly edited. In page 5 line 126 and 127 (previously line 117 page 5), the genus name "Drosophilia, Pyrocococcus, and Methanococcus" has been italicised.

\(9\) Page 9 line 198: "mutant Attrm5 R166D". Is this a gene name? If so, the words "a catalytic inactive" may be not appropriate.

Response- Page 9 line 219 (previously line 198), "mutant Attrm5 R166D" refers to the amino acid with mutated amino acid R (Arginine) to D (Aspartic acid). Hence, we retained the words "a catalytic inactive" to describe this loss-of-function protein at the catalytic site. To add clarity, we have also de-italicised Attrm5 which previously caused the confusion.

\(10\) Page 9 line 212: "T7 polymerase" -\> "T7 RNA polymerase".

Response- "T7 polymerase" has been edited to "T7 RNA polymerase" for page 9 line 233 (previously line 212 of the same page). We have also synchronised the usage of "T7 RNA polymerase" throughout the revised manuscript.

\(11\) Page 10 line 242: "S-adenosyl-methionine (AdoMet)". These words have already been described in Page 9 line 214.

Response- The words "S-adenosyl-methionine" in page 10 line 249 (previously line 242) were removed, while the term "S-adenosyl-methionine" will be first mentioned in page 10 line 266.

\(12\) Page 13 line 313: "KEGG annotation revealed enrichment of proteins involved in photosynthesis, and photosynthetic proteins". If possible, please add information whether the genes for these proteins are encoded in the nucleus genome. This information may help discussions in Page 17-18.

Response- The genome encoding information for the genes reported in the KEGG analysis has been included in page 13 line 340 and 341"...with most of these proteins encoded by genes found in the nuclear and chloroplast genome."

\(13\) Page 15 line 353: "suggesting that the loss of m1G37 and m1I37 affects tRNA half stability". The results in Figure 8 do not show the stability of tRNA half directly. Please revise the sentence. Page 18 line 438: "....5' half stability". Please revise the sentence by the same reason.

Response- Thank you we agree. Page 15 line 380 (previously line 353 of the same page) has been revised and edited to "...suggesting that the loss of m1G37 and m1I37 affects tRNA halve steady state abundance". We have also revised the sentence in page 19 line 473 (previously page 18 line 438) to " ... tRNA aminoacylation but does affect tRNA-Ala-derived 5' half steady state abundance".

\(14\) Page 15 line 355-364. In general, Ala-RS does not recognize the anticodon-loop. Therefore, the results by the authors seem to be reasonable. Please see this paper "Chong et al. Proc. Natl. Acad. Sci. USA 115, 7527-7532 (2018)".

Response- The findings from the suggested paper have been included in page 15-16 line 391 to explain our observations of reduced tRNA-Ala-derived 5' half steady state abundance, "One explanation to this observation can be attributed to the nature of alanyl-tRNA synthetases that recognizes G3:U70 of tRNA acceptor stem for tRNA charging instead of the anticodon region" , citing reference \[41\] Chong et al. (2018) "Distinct ways of G:U recognition by conserved tRNA binding motifs."

\(15\) Page 16 line 373: "a 60% reduction in m1G and m1I levels". The reduction in m1I level may be not 60%.

Response- This has been edited. Please refer to page 16 line 413 "With the 60% reduction of m1G and 75% reduction of m1I in trm5 plants".

\(16\) Page 24 line 575: "T7 polymerase" -\> "T7 RNA polymerase"

Response- "T7 polymerase" has been edited to "T7 RNA polymerase" throughout the revised manuscript.

Reviewer \#2:

Overall Response- We thank reviewer two for their largely positive review and address their comments below. We agree that some technical information was not adequately described or were described elsewhere in the materials and methods. We have now addressed these points. While reviewer 2 suggested one additional experiment, we note the Editor clearly stated that no additional experiments were required before publication.

1\) Based on the sequence alignment shown in Figure S2, it is unclear why the authors focused on this specific homolog, and not either of the other two identified genes, since conserved motifs are present in all three. Importantly, the sequence of ScTrm5 shown in figure S2B is not complete- seems to start somewhere in the middle of the protein sequence in this alignment (as opposed to S2A which shows the whole thing). The possibilities of redundant or overlapping functions, as has been now identified for many families of enzymes with similar gene duplications in multicellular eukaryotes, can not be ignored. If the authors choose not to look at these other enzymes and their activities through similar experiments, conclusions about the uniqueness or sufficiency of the studied AtTrm5 ortholog should be significantly tempered. For example, the residual m1G (\~30%) and m1I (\~10%) levels in the mutant plants were dismissed as being the result of modification at position 9, and while this is a possibility, the alternative explanation that these are the result of activity by the other proteins is not considered. The sequence alignments with the other two genes should be moved to the main results for transparency, along with addressing these issues.

Response- We have added a sentence, page 5 lines 133 and 134, that addresses why experiments focussed on AtTRM5. Also on page 6, lines 151-153, we acknowledge that some observations may be explained by AtTRM5B or AtTRM5C.

2\) For the recombinant protein activity assays, it seems that levels of m1G were measured by the MS assay (although not stated in methods where activity assay is described). However, details regarding how \"relative nucleoside level\" were determined and what this means are not provided. This is significant because if the relative level of 1.0 means 100% modification of G37, then the meaning of the \~1.5X modification at higher levels of enzyme is unclear. Same is true for m1I assay results.

Response- Thank you reviewer two. The materials and methods section were updated to include more technical information, page 6 lines 679-690. The y axis of figures 4 and 5 were updated.

3\) The description of data analysis for the deep sequencing results for modification shown in figure 5C are entirely missing, and the data are not clearly presented (greatly oversimplified) because there is no quantification of the results. For this type of approach, it seems that there would have been an analysis of large numbers of reads, so it is unlikely that there was quantitative conversion of the A37 nucleotide to the T or G that is reported in the mutant strains. What were the total numbers of reads, and percentages of T substituted (and other substitutions) vs. G substituted reads from each tRNA? If there was 100% conversion in every read, then this unusual situation (even in other well-studied examples of analyzing tRNA modificaitons by RNAseq there are sequencing errors and some biological signal from unreacted substrates) should be discussed. The sanger results for the trm5-1 mutant (5D) anyway suggest that this is unlikely, since a significant A peak due to (presumably) unreacted A37 is clearly visible in the trace.

Response- The materials and methods sub-section heading was edited to highlight the relevant section, page 25 line 625. Based on the reads of the GATK results (which the SNPs were validated to be significant), A -\> G conversions were consistently observed in trm5 mutants, with no A-\> T conversions in the data. As for the WT data, there is a mix of A-\> and A-\>G conversion, which is why the data has now been presented in a qualitative format. Figure 5 legend, page 37 line 1044 was edited to highlight the qualitative nature of the assay. Instead, a dichotomous system is adapted to explain the observation. As mentioned in our manuscript, despite base conversion can be used to determine the possibility of modification change on RNA sequences, it is also known that RNA modification stalls reverse transcriptase activity, hence highlighting the technical difficulty in obtaining high read coverage for quantitative analysis as we hoped for.

4\) The location of the GFP reporter fusion (N-or C terminal) is never identified, and description of the construct in the section about fluorescence references the previous section on cloning where GFP is never mentioned. This is relevant because GFP location could affect activity and/or localization of the protein, and certainly if a N-terminal GFP is used, it may not be able to detect mitochondrial signal, if there is one.

Response- The materials and methods section, page 21 lines 535-540, was edited to show that the GFP was a C-terminal translational fusion to TRM5.

5\) The description of the newly identified NLS is somewhat confusing- the implication seems to be that the identified importin-dependent NLS is unique to plant Trm5, but yet it is clearly in a highly conserved part fo the enzyme including with ScTrm5?

Response- This has now been addressed in the edited manuscript. According to Björk et al. 2001, EMBO J (2001)20:231-239, no known CLS or bipartite NLS signal was known from Trm5p. Our multiple sequence alignment results between Arabidopsis thaliana Trm5 homologues, especially AtTRM5 where the alpha-importin dependent NLS sequence is detected, and ScTrm5p showed only several amino acids were conserved in the region.

6\) Although it is hard to read figure 7, it is unclear whether figure 7B includes only down-regulated proteins, or all differentially expressed (up and down). If includes both, some presentation of the data that supports the statement that the downregulated ones were specifically over-represented in the photosynthesis related ones is needed.

Response- We agree that the resolution of Figure 7 was decreased in the PLoS PDF conversion system. The original uploaded imagine was a clear high-resolution figure. We disagree with the reviewer that the figure represents the downregulated photosynthesis proteins only. The GO and KEGG analysis takes into account both upregulated and downregulated proteins.

7\) Figure S6, which according to text validates the proteomics data, is missing from the manuscript I received for review. Therefore, this claim cannot be evaluated.

Response- We apologise for this error. Figure S6 is included in the resubmission.

8\) It is hard to evaluate the RNAseq and proteomics results since these are not performed by ribosome profiling (more easy to internally control and standardize). Validation with northern and western for these specific targets identified in Figure S5 (some of the 27, plus some controls) would be needed to confirm. These data are better reserved for a future study in the absence of additional validation or rationalization, especially in light of the inconsistencies described extensively in discussion.

Response- Some of these candidates are validated in Figure S6 western blot results (which we apologize for missing out this data during the previous submission). Our western blot results are consistent with our findings reported in the RNA-seq/Proteomics data.

9\) A control northern experiment for tRNA half levels for a non-substrate tRNA (such as the tRNAArg control) is needed to evaluate the specificity of the observed loss of tRNA half abundance- is this direction due to the loss of trm5 activity, or an indirect effect of the many other phenotypes identified earlier in the paper? Without these data, the conclusions made about this in discussion are somewhat overreaching.

Response- While it is possible that our result may be indirect or non-specific, we do clearly state the result "suggesting that the loss of m1G37 and m1I37 affects tRNA halve steady state abundance.", page 15 lines 381 and 382. We thank the Editor for clearly stating that no additional experiments were required before publication.

Editorial comments-

1\) The introduction needs proofreading and revision for clarity overall, including issues with English grammar/language.

Response- A number of edits have been made throughout the manuscript. Please see the "marked up" version of the manuscript. Examples includes page 2, lines 48 and 49.

2\) Figures are very low quality in the pdf version I got for review- should be addressed in revised version.

Response- High-quality figures were uploaded to the PLoS system but unexpectedly the PDF version of the combined figures and text had some low-resolution figures.

Data availability is clearly shown and available to the community- see page 34 line 976.

10.1371/journal.pone.0225064.r003
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Arabidopsis TRM5 Encodes a Nuclear-localised Bifunctional tRNA Guanine and Inosine-N1-methyltransferase that is Important for Growth

PLOS ONE

Dear Dr Searle,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Your manuscript has been evaluated by the same two reviewers as previously. Although Reviewer \#1 is now fully satisfied by your revised manuscript, Reviewer \#2 has expressed some concerns, particularly on the quality of your validation data (which were not available for review in the previous version). I have also read the manuscript myself and I would like to invite you to submit a new version addressing the points raised by Reviewer \#2 and myself.

As the link between Figure S6 and the proteomic data remains somewhat unclear (see the reviewer\'s comments below), I would suggest removing this figure from the manuscript, provided that you clearly state elsewhere in the manuscript that the results have not been subjected to validation by an alternative method. 

I am also asking you to supply additional information on some aspects of Supplementary Table S3, Please clarify how the p-values in the table have been adjusted (i.e. corrected for multiple testing), as this information is not included in the Methods section. Please note that if they have not been corrected, the validity of some of your conclusions might be compromised. In this table, please also include the raw values for each genotype (i.e. not only their ratios).

Please see below some additional minor comments. Note that PLOS ONE does not copyedit accepted articles, and all problems in the text must be fixed before acceptance.

We would appreciate receiving your revised manuscript by Nov 28 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Hector Candela, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Line 47: Split the two sentences \"\...mutants. However, \...\"

l\. 85: remove comma before \"catalyses\"

l\. 89: add a comma after \"TrmD\".

l\. 91: have -\> has

Line 150-151: \"in Arabidopsis thaliana\" is said twice

Line 186: Use uppercase characters for the gene name. Regulators -\> REGULATOR (no S)

Line 198: something is wrong in this sentence (\"a yeast\")

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors adequately addressed my concerns. I would like to suggest the accept of this revised manuscript.

Reviewer \#2: Revisions have been made in response to several issues raised previously. The presentation of the deep sequencing analysis for tRNA modification at position 37 is somewhat improved here, and the qualitative description of the results is ok, but as described, it is unclear exactly what these data add above what is clearly visible already from the sanger sequencing result in panel D. nonetheless, I do not have technical issues with the way it is presented now. However, the addition of the missing data from the last round has raised new questions that need to be addressed because they go directly to the issue of confidence in the interpretation that photsynthetic gene expression is affected specifically by loss of trm5.

1\) Now that western validation data are available, the interpretation that the results were consistent with the proteomics needs to be supported with much more analysis. I see no names of proteins identified in Figure 7 (call the dots out on the proteomics that were tested in the western, as is commonly done) or discussed in the text so that I can evaluate how the western data do, or do not, support the proteomics by a direct comparision.

\- major issue: there is no quantification provided in Figure S6- I see 6 proteins, with some whose levels seem to change to some extent relative to WT and some that don\'t appear to change as much, but of course this would require actual quantification in some way. The problem is normalization for loading, which the authors suggest is supposed to be done visually by the coomassie staining, although this is of course not appropriate at all because we are looking at one protein (which one?) and it is not the typical way to normalize by a protein western control signal for a protein that should not be changing. However, even trying to interpret this result (by eye) seems to clearly show heavier bands in the coomassie WT \"100%\" lane than in the corresponding trm5-1 lane. As presented, these data definitely do not meet typical standards for scientific rigor.

\- were some of these proteins controls that are used to show that levels did not change, as expected based on the proteomics?

\- I assume the 100% listed for trm5-1 indicates some fraction of the sample loaded, but this doesn\'t quite make sense- this is better phrased with some indication of exact total protein loaded per lane? This is a minor point, but would help improve clarity.

Bottom line, the superficial way the validation is performed and described significantly impacts the confidence in the proteomics data, which are a major conclusion of the paper.

2\) a related issue is with the RNAseq data used to suggest targets whose regulation is at the level of translation. Since validation of the RNAseq data are not provided (which is the standard in the field), and because now it is clear that the western validation (now shown) did not focus specifically on any of these proteins, and the quantitative data needed to rigorosuly support the validity of the proteomics are also absent (see point above), this result identifying some proteins whose may be regulated at the level of translation can not be viewed as well-supported by any current standards in the field. This highly speculative result could be removed to discussion, or quite honestly from the paper entirely, without further substantiation.

In short, this paper nicely demonstrates biochemical and biological functions for a homolog of the tRNA methyltransferase trm5 in A. thaliana. Results directed toward that goal ,and characterization of mutant plants, which already suggests interesting things to be followed up on, are a strength and are rigorously described. Beyond that, the attempts to delve deeper into underlying changes in gene expression are not well-supported by the data presented, which in many cases do not meet even the bare minimum of standards for critical analysis for these kinds of studies.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0225064.r004

Author response to Decision Letter 1
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Please find below a point-by-point response to the editor, reviewers one and two comments.

Reponses are in blue coloured font.

Editor's comments:

\(1\) Comment- As the link between Figure S6 and the proteomic data remains somewhat unclear (see the reviewer\'s comments below), I would suggest removing this figure from the manuscript, provided that you clearly state elsewhere in the manuscript that the results have not been subjected to validation by an alternative method.

Response -The supplementary figure S6, along with the figure captions and all previous mentions in the manuscript have been removed. We have also added a senetence that in the future that validation of the proteomics data will be required via quantitative western blotting to verify the direct or indirect effect of the loss of TRM5. Please refer to page 14 lines 324-327 of the manuscript for the edits.

\(2\) Comment- I am also asking you to supply additional information on some aspects of Supplementary Table S3, Please clarify how the p-values in the table have been adjusted (i.e. corrected for multiple testing), as this information is not included in the Methods section. Please note that if they have not been corrected, the validity of some of your conclusions might be compromised. In this table, please also include the raw values for each genotype (i.e. not only their ratios).

Response - Additional information on the proteomics data, including the raw values of each genotype have been included in the updated Supplementary Table 3. The p-values have been corrected using Benjamini-Hochberg (BH) correction method and the methods section in the manuscript has been updated accordingly. The BH corrected p-values have been included in supplementary Table 3.

Additional Editor Comments (if provided):

\(3\) Comment- Line 47: Split the two sentences \"\...mutants. However, \...\"

Response - The suggested edits were incorporated. The sentences are split into two at page 2 line 47-48.

\(4\) Comment- l. 85: remove comma before \"catalyses\"

Response -The sentence has been amended with the comma removed. Please refer to page 4 line 86.

\(5\) Comment- l. 89: add a comma after \"TrmD\".

Response - A comma has been added after TrmD. Please refer to page 4 line 89.

\(6\) Comment- l. 91: have -\> has

Response - This sentence was corrected as suggested. Please refer to page 4 line 91.

\(7\) Comment- Line 150-151: \"in Arabidopsis thaliana\" is said twice

Response - The redundant "in Arabidopsis thaliana" mentioned in the manuscript was removed as suggested. Please refer to page 6 line 151.

\(8\) Comment- Line 186: Use uppercase characters for the gene name. Regulators -\> REGULATOR (no S)

Response - The gene name PSEUDO RESPONSE REGULATOR 7 has been corrected to all upper-case characters at page 8 line 190.

\(9\) Comment- Line 198: something is wrong in this sentence (\"a yeast\")

Response - The sentence was amended by removing "..a yeast". Please refer to page 8 line 201.

\(10\) We proofread our manuscript prior to resubmission.

With this resubmission, we attached the corrected Fig 1, which in Fig 1 panel A and B the misspelled "SITRM5" has been corrected to "SiTRM5".

Reviewer \#1:

We thank reviewer 1 for the positive feedback on the manuscript revisions.

Reviewer \#2:

\(11\) Now that western validation data are available, the interpretation that the results were consistent with the proteomics needs to be supported with much more analysis. I see no names of proteins identified in Figure 7 (call the dots out on the proteomics that were tested in the western, as is commonly done) or discussed in the text so that I can evaluate how the western data do, or do not, support the proteomics by a direct comparison.

\- major issue: there is no quantification provided in Figure S6- I see 6 proteins, with some whose levels seem to change to some extent relative to WT and some that don\'t appear to change as much, but of course this would require actual quantification in some way. The problem is normalization for loading, which the authors suggest is supposed to be done visually by the coomassie staining, although this is of course not appropriate at all because we are looking at one protein (which one?) and it is not the typical way to normalize by a protein western control signal for a protein that should not be changing. However, even trying to interpret this result (by eye) seems to clearly show heavier bands in the coomassie WT \"100%\" lane than in the corresponding trm5-1 lane. As presented, these data definitely do not meet typical standards for scientific rigor.

\- were some of these proteins controls that are used to show that levels did not change, as expected based on the proteomics?

\- I assume the 100% listed for trm5-1 indicates some fraction of the sample loaded, but this doesn\'t quite make sense- this is better phrased with some indication of exact total protein loaded per lane? This is a minor point, but would help improve clarity.

Bottom line, the superficial way the validation is performed and described significantly impacts the confidence in the proteomics data, which are a major conclusion of the paper.

Response - The supplementary figure S6 has been removed from the manuscript after careful revision of this manuscript based on the reviewer \#2's comments.

\(12\) a related issue is with the RNAseq data used to suggest targets whose regulation is at the level of translation. Since validation of the RNAseq data are not provided (which is the standard in the field), and because now it is clear that the western validation (now shown) did not focus specifically on any of these proteins, and the quantitative data needed to rigorosuly support the validity of the proteomics are also absent (see point above), this result identifying some proteins whose may be regulated at the level of translation can not be viewed as well-supported by any current standards in the field. This highly speculative result could be removed to discussion, or quite honestly from the paper entirely, without further substantiation.

Response - We have edited the manuscript and have soften our results section according to the reviewer's suggestion. Please refer to page 14 lines 324-327 of the manuscript for the edits.

We thank reviewer 2 for the constructive feedback on the manuscript.
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Dear Dr. Searle,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Hector Candela, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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Arabidopsis TRM5 Encodes a Nuclear-localised Bifunctional tRNA Guanine and Inosine-N1-methyltransferase that is Important for Growth

Dear Dr. Searle:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hector Candela

Academic Editor

PLOS ONE
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